Back to search results

Pilot Study of Atibuclimab for Knee Osteoarthritis

This study is looking for 40 people aged 50 to 80 with knee osteoarthritis (KOA) to test a new treatment. Knee OA causes chronic pain and disability, and current treatments offer only short-term relief. This study will compare an intravenous (IV) injection of Atibuclimab to an IV infusion of saline (saltwater placebo). Researchers want to see how many people are willing to join the study and how many actually get assigned to a treatment. To be eligible, you must have knee OA confirmed by specific criteria, experience pain of at least 5 on a visual scale, and have joint swelling. You cannot have had a serious infection recently or poorly controlled crystal arthritis.

Study design
This is an interventional study planning to enroll 40 participants. It will compare two treatments: Atibuclimab and saline placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is to measure screening and randomization rates over 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07481474

Pilot and Feasibility Study of Anti-CD14 for the Treatment of Knee Osteoarthritis

Not Yet Recruiting
PHASE1Ages 50–80InterventionalTreatment
VA Office of Research and Development
~40 participants
Updated 2026-07-15 on ClinicalTrials.gov
What's tested:Atibuclimabsaline placebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rates of screening and randomization
Measured over 2 years

Conditions

Knee Osteoarthritis (Knee OA)

Explore related trials

Osteoarthritis of knee

NCT07481474

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

    Philadelphia, Pennsylvaniastudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Joshua F. Baker, MD MSCE · PRINCIPAL_INVESTIGATOR · Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

Who to contact

Joshua F Baker, MD MSCE
[email protected]
(215) 823-5800
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

ACR Classification Criteria for Knee Osteoarthritis
Pain \>=5 on Visual Analogue Scale
Kelgren-Lawrence Grade \>1
Joint Effusion on Exam
Able to provide informed consent

Exclusion

Serious or hospitalized infection in last 1 year
Poorly controlled crystal arthritis in last 6 months
Pain Pressure Threshold (PPT) testing \<=3
History of diagnosed fibromyalgia
Receipt of corticosteroid in affected knee within 3 months
Receipt of visco-supplementation or other intra-articular therapy (other than corticosteroid) within 6 months
Ongoing participation in another interventional study
Inability to ambulate without assistive device
Pregnancy or Lactation
History of knee arthroplasty in either knee
Symptomatic heart failure
Glomerular filtration rate \<45
Class III obesity (BMI\>40 kg/m2)
Recent active malignancy (chemotherapy, radiation, or surgery within 3 months)
Poorly controlled diabetes (A1c\>8%)
Rheumatoid Arthritis
Psoriatic Arthritis

What this trial measures

  • Rates of screening and randomization2 years

    The number of randomized participants relative to the number screened. The screening protocol will be considered feasible if 1/2 of screened patients are eligible to be randomized.